argenx SE — FY2023 Form 20-F
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter report; the supplied filing text does not provide a clear Q4-only financial breakdown. Financial statements are prepared under IFRS as issued by the IASB and reported in U.S. dollars.
Business context and financial highlights
argenx is a commercial-stage biotechnology company focused on severe autoimmune diseases. Its principal marketed products are intravenous VYVGART and subcutaneous VYVGART SC for generalized myasthenia gravis (gMG). The company is also developing efgartigimod in additional indications and advancing empasiprubart and ARGX-119.
| Metric | FY2023 | FY2022 |
|---|---|---|
| Product net sales | $1,190.8 million | $400.7 million |
| Total operating income | $1,268.6 million | $445.3 million |
| Cost of sales | $117.8 million | $29.4 million |
| Research and development expense | $859.5 million | $663.4 million |
| Selling, general and administrative expense | $711.9 million | $472.1 million |
| Operating loss | $(425.0) million | $(720.3) million |
| Net loss | $(295.1) million | $(709.6) million |
| Basic and diluted loss per share | $(5.16) | $(13.05) |
| Operating cash flow | $(420.3) million | $(862.8) million |
Product net sales grew 197%. Approximate gross margin was 90.1% (versus 92.7% in 2022); operating margin was approximately negative 33.6%, and net margin approximately negative 24.8%. These ratios are calculated from reported figures. The company remained loss-making, with accumulated losses of $2.405 billion.
Cash, liquidity and capital
- Cash and cash equivalents were $2.049 billion and current financial assets were $1.131 billion at year-end, totaling $3.180 billion, up from $2.193 billion in 2022.
- Total assets were $4.542 billion; total equity was $4.098 billion. Current liabilities were $423.0 million.
- The company reported no financial borrowings; lease liabilities totaled $20.0 million ($4.6 million current and $15.4 million non-current). It also disclosed a $7.2 million line of credit.
- Financing cash inflow was $1.337 billion, principally reflecting net proceeds from the July 2023 offering. The offering raised $1.3 billion gross and $1.2 billion net; 2,581,633 shares, including shares represented by ADSs, were issued.
- Management stated that available cash and current financial assets were expected to fund operating and capital requirements for at least 12 months, and that working capital was sufficient for present requirements for at least 12 months from the report date.
Material changes versus FY2022
- Commercial sales scaled substantially, from $400.7 million to $1.191 billion. The U.S. generated $1.047 billion, about 88% of product net sales; Japan contributed $56.4 million, EMEA $72.9 million and China $14.9 million.
- Operating loss narrowed by 41% and net loss by 58%, helped by higher product sales, interest income and foreign-exchange gains. Expenses nonetheless increased: R&D rose 30% and SG&A 51% as the company expanded trials and commercial operations.
- Operating cash outflow declined to $420.3 million from $862.8 million, primarily as product sales increased; inventory, prepaid inventory and operating expenses continued to consume cash.
- Financial income increased to $107.4 million from $27.7 million, mainly due to higher interest income. Foreign-exchange results shifted to a $14.1 million gain from a $32.7 million loss.
Outlook, clinical developments and risks
- Management expects continued investment in commercialization, supply capacity, clinical development and the discovery pipeline, with operating expenses expected to increase. The filing text supplied here does not provide a clear numerical 2024 revenue or earnings guidance figure.
- VYVGART and VYVGART SC were approved in multiple markets for gMG. The company reported more than 6,000 gMG patients treated globally by year-end and approvals in more than 30 countries or regions across the products.
- Positive Phase 3 ADHERE results in CIDP supported an FDA supplemental application, accepted for priority review with a June 21, 2024 target date. The company also reported a Japanese filing for IV VYVGART in ITP, with a decision expected in Q1 2024.
- Clinical setbacks included the Phase 3 ADVANCE-SC ITP trial, which missed its primary and secondary endpoints, and the Phase 3 ADDRESS pemphigus trial, which did not meet its primary endpoint. Argenx stopped further pemphigus development and halted enrollment in the related BALLAD bullous pemphigoid trial pending a revised plan.
- After year-end, in January 2024, argenx reported positive first-cohort Phase 2 data for empasiprubart in multifocal motor neuropathy, including a reported 91% reduction in need for IVIg rescue versus placebo. This is a subsequent-period update, not FY2023 revenue or a completed pivotal result.
- An unusual manufacturing item: a latent defect was identified in drug-substance batches produced in 2022 at a facility awaiting approval. The company reduced inventory by $47.3 million and recorded a $47.3 million non-current prepayment after the supplier committed to replace the material in future years.
- Risks include continued losses and uncertain profitability; dependence on VYVGART sales and market access; competition, pricing and reimbursement pressure; clinical and regulatory uncertainty; reliance on third-party manufacturers and distributors; foreign-exchange and investment risks; and potential effects of healthcare policy changes. Four U.S. customers represented approximately 86% of U.S. product net sales.
- The auditor issued unqualified opinions on the financial statements and internal control over financial reporting. The critical audit matter was U.S. gross-to-net revenue adjustments, which rely on estimates and third-party data subject to timing delays.
Most important facts for investors to verify
- Whether VYVGART sales growth, payer coverage, pricing and international launches remain sufficient to offset commercial and development spending.
- The assumptions and subsequent true-ups behind gross-to-net deductions, which reduced FY2023 gross sales by $151.4 million.
- FDA action on the CIDP application and the status and results of other key clinical programs, including the implications of the ITP and pemphigus failures.
- Supplier performance and timing of replacement for the $47.3 million affected drug-substance batches, as well as broader manufacturing capacity and supply reliability.
- Cash consumption and financing needs against management’s stated 12-month liquidity assessment, including the effect of continued investment and equity issuance.
- Revenue concentration in the U.S. and among a small number of customers, and the effects of government rebates, pricing rules and reimbursement negotiations.